Italys health minister has proposed sectioning people who refuse hospital treatment for Covid-19 and has suspended flights from Bangladesh as the southern European country grapples with several new coronavirus outbreaks.
The potential move towards forced hospitalisations came after a cluster of infections arose in the northern Veneto region, triggered by a man who developed coronavirus symptoms on the day he returned from a business trip to Serbia and initially resisted treatment in hospital.
The 64-year-old, from Vicenza, is now in a serious but stable condition in hospital. Five others tested positive and 89 people were quarantined after he attended a funeral and birthday party at which there were more than 100 guests.
I am evaluating with my legal department the hypothesis of compulsory health treatment in cases where a person must be treated but [refuses] to be, Roberto Speranza, the health minister, said. At the same time, my thoughts on how Italians have behaved during this crisis are positive, as without this fundamental harmony we would not have bent the [rate of infection] curve.
Speranza also warned that those with Covid-19 who break isolation rules face jail and that the 14-day quarantine measure for people arriving in Italy from countries outside of the Schengen area must be adhered to.
Under Italian law, anyone who negligently spreads an epidemic risks a prison sentence up to 12 years, while anyone who does so wilfully may face up to life imprisonment.
Luca Zaia, the president of the Veneto region, also called for forced hospitalisations and has introduced 1,000 fines for people who flout quarantine rules. He said that until the end of July hospitals must tell the public prosecutors office of anyone refusing admission after testing positive.
Until the recent flare-ups Veneto was hailed for successfully containing the contagion despite being a hotspot at the beginning of Italys pandemic. Another outbreak occurred in the city of Padua when a person returning from Moldova infected 10 others.
Italys Trattamento Sanitario Obbligatorio (mandatory medical treatment) is usually applied only in mental health cases, but can be enforced on those with an infectious disease.
Corriere della Sera reported that the measure had already been taken against an elderly woman from Monza in Lombardy, the region worst affected by the virus, who in early March refused hospital care despite presenting serious symptoms.
The minister said he suspended flights from Bangladesh for a week after a significant number of the over 200 passengers who arrived at Romes Fiumicino airport on Monday from Dhaka tested positive. The tests were enforced after an outbreak among the Bengali community in the Lazio region, where 12 of the 19 cases registered on Monday originated from those had recently returned from Dhaka.
After all the sacrifices made we cannot afford to import infections from abroad, Speranza said. Better to continue to follow the line of utmost caution.
At a national level, the infection and death rate have slowed significantly since Italy began easing lockdown restrictions in early May, with 208 new cases and eight fatalities recorded on Monday. But 19 clusters have emerged across the country since the middle of June, according to a report in Corriere della Sera over the weekend.
The biggest outbreak so far has occurred in Bologna, in Emilia-Romagna, where by early July 117 workers at a courier firm were infected with the virus. In late June, the army was sent to Mondragone, a town near Naples, to seal an apartment complex where an outbreak had occurred among Bulgarian farm workers. Seven hundred residents were quarantined, with 73 testing positive for Covid-19 by 4 July. The next significant outbreak has been in Mantua, a city in Lombardy where 52 infections were detected among workers at two meat factories.
Nicola Zingaretti, the president of Lazio and leader of the Democratic party, one of the parties governing nationally, on Tuesday urged people to respect the rules in order to not waste the sacrifices that have been made.
`;articleContent = document.querySelector(".article-content");articleContent.innerHTML = articleContent.innerHTML + formbox;function waitForElement(id, callback){ var goStahp = setInterval(function(){ if(document.getElementById(id)){ clearInterval(goStahp); callback(); } }, 100);}waitForElement("customAnvatoPlayerForHowTipsBecomeStories", function(){ AnvatoPlayer("customAnvatoPlayerForHowTipsBecomeStories").init({url: "https://ep-lin-publish.storage.googleapis.com/videos_lin/variant/5541156.m3u8",width: "100%",poster: "https://www.kxan.com/wp-content/uploads/sites/40/2020/05/Featured-Image-Tip-Form-Video.jpg","share" : 0,"mcp":"LIN","plugins":{"googleAnalytics":{"trackingId":"UA-32507368-26","events":{"VIDEO_STARTED":{"alias": "How a Tip Becomes A Story - videoContentPlay","category":"Video"},"VIDEO_FIRST_QUARTILE":{"alias": "How a Tip Becomes A Story - video 25%","category":"Video"},"VIDEO_MID_POINT":{"alias": "How a Tip Becomes A Story - video 50%","category":"Video"},"VIDEO_THIRD_QUARTILE":{"alias": "How a Tip Becomes A Story - video 75%","category":"Video"},"VIDEO_COMPLETED":{"alias": "How a Tip Becomes A Story - videoComplete","category":"Video"},"USER_PAUSE":{"alias": "How a Tip Becomes A Story - videoPause","category":"Video"}}},}});});
Nearly one in six Britons will refuse a coronavirus vaccine if and when one becomes available, and a similar number are unsure whether they will get one, according to a survey.
The findings come amid a significant rise in anti-vaccination sentiment on social media, and represent a threat to efforts to contain the disease.
Our hope for a return to normal life rests with scientists developing a successful vaccine for coronavirus, said Imran Ahmed, the chief executive of the Center for Countering Digital Hate (CCDH), a non-profit organisation that commissioned the research. But social media companies irresponsible decision to continue to publish anti-vaccine propaganda means a vaccine may not be effective in containing the virus. The price for their greed is a cost paid in lives.
According to the polling carried out by YouGov for CCDH, 16% of British adults probably or definitely will avoid a Covid-19 vaccine. The poll of 1,663 people found differences between those who get the majority of their news from social media and those who rely more on traditional media: the latter were nine percentage points more likely to say they would definitely or probably get the vaccine.
The 150 largest anti-vaccination social media pages and YouTube channels tracked by CCDH have collected about 8 million more followers since the beginning of the coronavirus crisis, and the 400 outlets in the sample have a combined 55 million followers.
Some of those pages have published false conspiracy theories including that Bill Gates created the pandemic, that vaccines cause Covid-19, and that tests for a coronavirus vaccine have caused women to become infertile.
The majority of the followers are on Facebook, despite the company officially opposing anti-vaccination content. In July 2019 the company announced policies to reduce the spread of posts with exaggerated or sensational health claims.
A Facebook product manager said at the time: People come together on Facebook to talk about, advocate for, and connect around things like nutrition, fitness and health issues. But in order to help people get accurate health information and the support they need, its imperative that we minimise health content that is sensational or misleading.
As well as so-called organic sharing, both Facebook and Twitter have enabled advertising opposing vaccination, despite bans on such promotions on both sites. Those adverts come from influencers including David Wolfe, described by the CCDH as an anti-vaccine wellness guru, who promoted a popular panacea, colloidal silver, as my #1 recommendation under the current crisis.
The group said: Other adverts featured Judy Mikovits anti-vaxx conspiracy theories, who featured in the notorious Plandemic film, and adverts placed by Robert F Kennedy Jrs Childrens Health Defense campaign that promote health misinformation about both vaccines and 5G mobile phone signals.
Advertisers can target their promotions at users who Facebooks algorithm has decided may have interests such as vaccine-preventable diseases or who have liked the page Talk About Curing Autism. On Twitter, advertising categories such as antivaxx and natural immunity are available for all to use.
This sophisticated ecosystem has grown by exploiting weaknesses in each social media companys policies on anti-vaxx and health misinformation, Ahmed said. Each platform plays a role in feeding and growing the whole.
Full-time anti-vaxx campaigners doubled their reach by broadcasting their message on YouTube channels that peddle conspiracy theories and false cures. In turn, these campaigners lend their brand and audience of activists to a thriving industry of anti-vaxx entrepreneurs using Facebook as a shopfront.
Ahmed added: Both groups have benefited from the reach of professional conspiracists on YouTube and from a network of Facebook groups that turns vaccine sceptics into true believers using psychological hacks like the dopamine hit for likes and the fear of abuse for nonconformity.
In a statement, a Facebook spokesperson said: We are working to stop harmful misinformation from spreading on our platforms and have removed hundreds of thousands of pieces of COVID-19-related misinformation. We reduce vaccine misinformation in News Feed, we dont show it in search results or recommend it to you on Facebook or Instagram, we dont allow it in ads, and we connect people with authoritative information from recognised health experts.
Only 1 of the 8 people is showing symptoms, according to the Newberg School District.
NEWBERG, Ore. Eight people associated with a youth baseball team that includes students who attend Newberg High School or other nearby schools have tested positive for COVID-19, the Newberg School District confirmed.
During a weekend tournament in Roseburg, the Newberg team learned that a team from Roseburg had reported two cases of COVID-19 among their players, according to Newberg School District Superintendent Dr. Joe Morelock.
The Newberg team had no contact with the Roseburg team but they decided to leave the tournament early anyway, Morelock said.
On Friday, July 3, one of the Newberg players tested positive for COVID-19. Everyone associated with the team was notified and told to be tested for COVID-19. As of Monday afternoon, eight people associated with the team have tested positive for the virus.
Only one of the eight people who have tested positive for COVID-19 is showing symptoms.
Morelock said all contact tracing and social distancing protocols have been followed and the team is working with Oregon Health Authority. The names of students and adults who have tested positive will not be released.
The United States will know by the end of the year or the beginning of 2021 whether a coronavirus vaccine is safe and effective, Dr. Anthony Fauci, the nation's leading infectious diseases doctor, said Monday.
Multiple vaccine candidates are being studied, and "if things go the way it looks like they're going, one of these will enter phase 3 at the end of July," he said, referring to the final phase of clinical trials needed to determine whether a drug works.
Full coverage of the coronavirus outbreak
Other vaccine candidates will enter phase 3 trials after July, and "we hope that by end of this year, or the beginning of 2021 we will at least have an answer whether the vaccine or vaccines - plural - are safe and effective," Fauci, who is the director of the National Institute of Allergy and Infectious Diseases, said.
He took part in a conversation with Dr. Francis Collins, director of the National Institutes of Health, on Facebook Live on Monday as new cases of COVID-19 continue to surge in the U.S.
"The current state is really not good," Fauci said, adding that two days ago, there were 57,500 new cases in the U.S.
"We are still knee-deep in the first wave of this," he said. Referring to the recent increases in cases, he went on, "I would say this would not be considered a wave, it was a surge or a resurgence of infections superimposed upon a baseline, Francis, that really never got down to where we wanted to go."
Let our news meet your inbox. The news and stories that matters, delivered weekday mornings.
Much of the conversation focused on vaccine development.
To ensure that a vaccine will be available soon after clinical trials are complete, Fauci said, the National Institutes of Health is working with companies to start making doses of the drug before it's known whether it works or not.
And if the vaccine doesn't turn out to be safe and effective? Those doses will just have to be thrown out, he said. "But that is a financial risk, it is not a risk for safety, nor is it risk for scientific integrity," he added.
Collins acknowledged that the government's name for the development of a coronavirus vaccine dubbed "Operation Warp Speed" may give some the impression that scientists may be cutting corners for safety.
"I want to assure everybody because you and I are in all these conversations, often many times a day and late into the night that there will be no compromising on the principles of safety and efficacy," he said. "Whatever we come up with in a few months is going to be just as rigorously tested as any vaccine ever has been."
The phase 3 trials will include 30,000 people, half of whom will receive the vaccine and half of whom will not. The trials will take place in areas where there are high levels of transmission, possibly including locations outside the U.S.
The researchers will also aim to include people in high-risk groups.
Download the NBC News app for full coverage of the coronavirus outbreak
Fauci said that he and Collins are "making sure that the trials are quite well represented by the individuals who are most susceptible, not only to infection because of certain circumstances in their life, but also the fact that they are more prone to complications because of underlying comorbidities."
He also acknowledged that we don't yet know the answer to how long protection from the vaccine will last. "We're going to assume that there's a degree of protection, but we have to assume that it's going to be finite protection," Fauci said, adding that follow-up research will be needed to determine if and when people need a booster.
Collins struck an optimistic tone on vaccine development. "Youre saying this is a pretty good virus for a vaccine to work. It has the ability where natural infection does seem to be protective. It doesn't seem to mutate too rapidly compared to some others. Is that fair?"
"That is fair," Fauci agreed. "Its an RNA virus and as we know, RNA viruses mutate, but the functional consequence of that mutation so far doesnt look to be impressive."
Collins and Fauci ended the conversation urging the American people to stick with the public health guidance.
"It will end," Fauci said. "We will get through this. Hang in there. It will end, we promise you."
Follow NBC HEALTH on Twitter & Facebook.
Sara G. Miller is the health editor for NBC News, Health & Medical Unit.
The U.S. government has awarded a $1.6 billion contract to Novavax, Inc. to develop a coronavirus vaccine.
The award to the Maryland-based company is the largest to date from the governments Operation Warp Speed initiative to fast-track the development of vaccines and other treatments for COVID-19.Chief Executive Stanley Erck said the company aims to begin delivering 100 million doses of a vaccine in the fourth quarter of this year, an endeavor he said that may be completed by January or February of next year.
Report: Britain Nears $625 mln Sanofi/GSK COVID-19 Vaccine Deal
Clinical trials are due to start in September and Sanofi has said it expects to get approval by the first half of next year, sooner than previously anticipated
The U.S. Health and Human Services Department and the Defense Department said in a joint statement that because the federal government funded the initiative, they will own the 100 million doses of investigational vaccine expected to result from the demonstration projects.
The award was granted as the number of new infections are surging in the U.S., the world leader in infections and fatalities, prompting a growing number of states and cities to reimpose lockdown measures.
The countrys preeminent infectious disease expert, Dr. Anthony Fauci, warned in an interview Monday the U.S. is still knee-deep in the first wave of this pandemic.
Novavaxs stock price soared in premarket trading on the news it had received the government funding.
WATCH: VOA Interview -Dr. Fauci optimistic about vaccine
Sorry, but your browser cannot support embedded video of this type, you can download this video to view it offline.
The advent of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic and the dynamics of its spread is unprecedented. It is therefore, of paramount importance to get a vaccine that can stop the spread of the virus.
But basic knowledge about the virus and kinetics of immune responses against it is still emerging. An added difficulty is that different strains of SARS-COV-2 have been reported even in the same country within six months of its emergence.
Read more: Mutating coronavirus: what it means for all of us
Vaccines are preventive or therapeutic interventions that dramatically reduce morbidity and mortality caused by infectious diseases. They are clinically simple but immunologically complex. Edward Jenner is considered to be the father of vaccinology because he developed the first vaccine to prevent smallpox over 200 years ago. This led to the global eradication of the disease and the development of more life vaccines.
Over the intervening two centuries vaccinology has developed into a multidisciplinary intervention. It involves scientists from fields such as microbiology, immunology, medicine, epidemiology, statistics, policy, manufacturing, molecular biology, public health and even ethics.
All these disciplines are being deployed in the search for a vaccine against SARS-CoV-2.
Generally, good vaccines have three essential features.
First, they must be safe to administer.
Second, they must produce the appropriate type of immunity (antibody and/or cell-mediated) for the disease in question.
Third, they must be inexpensive for the target population and they must take into account geographical, gender and age differences.
To achieve these features, vaccine development undergoes a sequence of carefully implemented ethical processes and procedures. These are staged into pre-clinical and clinical development with four developmental phases which usually span a number of decades. This is because theres a need to understand the mechanisms of protection against the pathogen, and to mitigate the potential risk of vaccine-induced adverse reactions.
This takes time. And variations almost invariably emerge.
For example, geographical variation was reported in the efficacy of the rotavirus vaccine. In Malawi and South Africa its efficacy was found to be between 49% and 77%.. But in developed countries it was 95%-96%. A recently completed study in our laboratory showed that the roundworm, Ascaris, affected the efficacy of oral rotavirus and poliovirus vaccines.
Similarly, geographic or other variations could be encountered in the development of a vaccine for COVID-19 given that cardiovascular diseases, asthma, diabetes and ageing have been reported to aggravate the infection.
Immunologically, every antigen, including vaccine, is processed by the first line of defence, the innate immune system, and if need be passed on to the adaptive immune system.
These two lines of defence are tightly linked and finely controlled to attack different antigens in different ways. The aim is to eliminate the antigens while avoiding unintended damage to the healthy parts of the body.
Vaccine effectiveness is solely dependent on the adaptive arm of immune response. In this arm, specialised cells including the B cells and T cells are the major players. They have precise specificity for germs and provide long-term protection.
When a kind of blood cell, B lymphocyte, is in contact with foreign particles it multiplies to produce many plasma cells. These secrete antibodies whose major function is neutralisation of pathogens. In the development of a COVID-19 vaccine, researchers must identify a small part of coronavirus that will elicit effective neutralising responses.
Antivirus vaccines that lead to production of non-neutralising antibodies can facilitate deposition of complexes in tissues and activate several pathways that can worsen pathologies associated with the viral infection or excessive production of inflammatory cytokines as reported in some patients with severe COVID-19. This clearly indicates that when a protective immune response is compromised, massive damage to vital organs such as the lung, liver and the kidney can occur. Thus, damaging immune responses should be avoided by any COVID-19 vaccine.
Another blood immune cell in vaccine efficacy is the T lymphocytes. For effective COVID-19 vaccine, careful activation of certain types of T cells and monitoring of their pattern of responses are essential. For example, two types of T-lymphocytes (CD8+ T cells and CD4+ Th-1 responses) are required for the removal of SARS-CoV-2. But CD4+ Th-2 responses are not responsible for the elimination of SAR-CoV-2. It is well known that accentuation of Th-2 responses supports eosinophil recruitment, airway hyper-responsiveness, mucus production, and can weaken cytolytic T cell activity to cause delayed viral clearance and airway dysfunction. This type of unwanted response has been reported after vaccination against respiratory syncytial virus infection.
The pressure to develop a COVID-19 vaccine is huge. But its development without fully understanding the kinetics of immune responses involved in the disease and the safety risks of the vaccine could bring unwarranted setbacks now and in the future.
In addition, SARS-CoV-2 might mutate in ways that would make previously effective vaccines useless.
A great many steps have to be taken in the development of any vaccine. With COVID-19, there are added complexities given that its severity appears be different across gender and age. Theres also evidence that it might be mutable and that it has different strains. Then theres the fact that its very new, which means theres still limited knowledge about immune responses to SARS-CoV-2.
In addition, a multiplicity of disciplines must be involved. A safe and effective vaccine wont be developed without detailed understanding of host-pathogen interaction. This is happening in the trials that are being currently run.
What this adds up to is that a safe and efficient COVID-19 vaccine might not be realised soon.
South Africa recently announced the start of the countrys first COVID-19 vaccine clinical trial. The vaccine is also being tested in the UK and Brazil. Ina Skosana spoke to the vice-president for research at the South African Medical Research Council, Professor Jeffrey Mphahlele, to find out more.
The trial is a joint effort between different stakeholders. The main player is the University of the Witwatersrand, under the leadership of Professor Shabir Madhi. The South African Medical Research Council is co-funding the project with R10 million. Other funders include the Bill and Melinda Gates Foundation and vaccine developers at the University of Oxford.
In South Africa the aim is to vaccinate around 2000 volunteers. This will happen in at least three different groups. Half of the participants will receive the experimental vaccine and half will receive placebo. Theyll be followed for about a year to assess the safety of and the immune response to the experimental vaccine.
Before enrolling the large group of volunteers, the trial will start with a group of about 50 HIV negative healthy volunteers to evaluate the vaccine safety and to a limited extend immune response. Later, the trial aims to investigate the vaccine safety and ability to mount the immune response in HIV positive volunteers. Its important to test the vaccine in a participants with HIV given the high burden of HIV and AIDS in South Africa and the continent.
Its prudent to evaluate the safety of the vaccine in this group during the clinical trial and not to wait until the vaccine is licensed. Even so, the vaccine, once licensed, will be for everybody.
At this stage, this particular vaccine candidate (ChAdOx1) is being tested in South Africa, Brazil and the UK.
If and when the vaccine is licensed, the aim is to make it a public good and available to all countries in the world rich and poor.
Its critical that developing countries are involved in clinical trials because its important to test the vaccine in different populations.
If the vaccine candidate is developed and tested in high income countries only, the efficacy may not necessarily be the same in populations living in low- and middle-income countries.
This has happened with vaccines before.
One example was the rotavirus vaccine candidates. The purpose of the rotavirus vaccine is to protect against dehydration and severe gastroenteritis. Early vaccine candidates demonstrated high efficacy of over 80% when tested in developed countries with low child mortality. But when the same vaccines were tested in low-income and middle-income countries of Africa and Asia, the efficacy was between 40% and 65%.
That did not rule out the use of rotavirus vaccines in the developing world. In fact, research has now shown that there has been a significant reduction in hospital or emergency unit admissions for acute rotavirus gastroenteritis, or mortality in children under five years old, in countries with rotavirus vaccination programmes. This was particularly true for low-income and middle-income countries with high child mortality.
There are a number of reasons why vaccine efficacy differs. These include the genetic background of the population. With the rotavirus vaccine, additional factors that are thought to affect optimal vaccine efficacy may include early age of first infection before administration of the first vaccine dose, maternal antibodies, distinct medical problems (high levels of HIV, TB, malaria, high background of enteric infections and malnutrition), and unique diversity of circulating rotavirus strains not included in the vaccines.
In the case of COVID-19 the virus seems to be genetically stable. This is a big plus.
The most important challenge is the fact that a clinical trial is being conducted in the middle of a pandemic. It means that countries are having to deal with managing a public health emergency while simultaneously setting aside resources to do research.
Public health emergencies demand a response programme that is effective and nimble. No doubt the number one priority is to save lives and contain the epidemic. The recent Ebola outbreak in West Africa was a game changer in many ways. The outbreak spiralled out of control to become a global public health emergency due to a number of factors ranging from poor health systems to lack of medical innovations. When the cause of public health emergencies is known or predictable, and the tools to respond and intervene are widely available, it is always easy to respond and save lives.
We have learned a great deal since Ebola and other outbreaks. A key lesson is that research should take centre stage and become the norm in responding to a public health emergency especially when the cause is unknown or novel like with SARS-CoV-2. Rapid and responsive research during a public health emergency should aim to optimise and field test development of new health interventions such as vaccines, therapeutics and rapid diagnostic tools. It should also include socio-behavioural research, medical anthropology research and applied and translational research.
Read more: Ebola in the DRC: the race is on between research and the virus
In the case of the COVID-19 vaccine trial in South Africa, rising numbers of infections create a conducive environment to conduct the trial because high levels of infections are needed to field test the vaccine efficacy. Doing this clinical trial at a time of low infections would take longer to yield such results. But now that the cases are spiking, we should be able to know sooner if the vaccine is likely to work or not.
As indicated above, this is not the first time research is conducted in the middle of an outbreak. Weve got experience from Ebola, and other pathogens that were associated with outbreaks and epidemics like the original SARS, the MERS coronavirus and the Zika virus. These viruses were associated with epidemics obviously not to the same magnitude as SARS-CoV-2.
Read more: Mutating coronavirus: what it means for all of us
We just need to keep a balance between saving lives and doing research. In a pandemic like this one, the priority is to save lives. But theres a limit in what we can use to save lives unless research innovation takes centre stage. Initially, the focus was on diagnostic tests. This has now shifted to treatment and the prevention regimens.
Were making strides in treatment and prevention strategies. Recent breakthroughs include the use of remdesivir from the US and dexamethasone from UK for COVID-19 related treatment.
Clinical trials are standardised so I dont see this trial being different from others. Researchers should conduct trials following established legal, ethical and regulatory procedures governing conduct of trials. These include, but are not limited to, obtaining clearance from the South African Health Products Regulatory Authority and institutional Human Research Ethics Committees.
As COVID-19 vaccines near final stages of testing, governments are also racing against each other, busy securing supply for their own countries even before key efficacy data readouts.
After signing on AstraZeneca and partner Oxford University for 100 million doses of their COVID-19 vaccine candidate, the U.K. government is nearing a 500 million ($625 million) deal with GlaxoSmithKline and Sanofi to buy 60 million doses of their investigative shot if it later proves successful, The Sunday Times reported.
The deal, the first for the vaccine, is expected to be announced in the coming days, the British newspaper said, citing people familiar with the matter.
De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools
This webinar will describe strategies to mitigate risks, reduce attrition and help improve the quality and safety of your drug candidate.
Sanofi and GSK joined forces in April. For their candidate, Sanofi is contributing S-protein COVID-19 antigen based on its recombinant DNA technology thats also used in its seasonal flu vaccine Flublok, and GSK is offering its vaccine booster AS03.
The U.K. government is clearly eager to pre-empt supply, as initiation of first-in-human clinical trials of the Sanofi-GSK vaccine isnt expected until September. Securing stock at this early stage reflects its fear of being excluded given that the island nation is reliant on imports of most vaccines, including those for seasonal flu. The government has anticipated this and is pre-ordering COVID-19 vaccines, a source told The Sunday Times.
Its also likely rattled by Sanofi CEO Paul Hudsons earlier comment that the U.S. would be given first access to the vaccine in return for its financial support. That statement was soon backtracked by Sanofi Chairman Serge Weinberg after backlash from France.
REALTED:Sanofi chose a proven platform over speed in its COVID-19 vaccine hunt, CEO says
Prior to the upcoming Sanofi-GSK deal, the British government ordered 100 million doses of another potential COVID-19 vaccine, dubbed AZD1222, froma collaboration between AstraZeneca and the University of Oxford.
A phase 2/3 study of AZs adenovirus-based shot kicked off late May, though phase 1 data remain under wraps. In addition to its home country, AZ has also won backing from the U.S. HHS Biomedical Advanced Research and Development Authority (BARDA) witha $1.2 billion deal that entails delivery of about 300 million vaccine doses starting this fall. A few days ago, the drugmaker penned another deal valued at $127 million to produce 30 million doses of AZD1222 for Brazil.
Besides the two European candidates, U.S. drugmakers Moderna, Johnson & Johnson, Merck & Co. and Pfizerwhich is working with German firm BioNTechare also working on their COVID-19 vaccinesbacked by the Trump administrations Operation Warp Speed.
SALISBURY, Md. - If a vaccine for COVID-19 were to come out tomorrow, would you get in line? Recent polls find most people would want it, but many aren't so sure. People in Salisbury have mixed opinions.
A survey done by the Pew Research Centersays seven in 10 people would definitely or probably get the vaccine if it were available. Some people in Salisbury say they'd want to protect themselves.
"Because I want to be protected from it. I haven't got coronavirus and I don't want to get it,"Matilda Tull of Salisbury says.
Some say they'd also want to protect others.
"Because well first of all I have elderly parents who I'm quite worried about their health and if I were to get sick myself, I could possibly pass it on to them. So I want to protect my family,"Charles Baldwin of Salisbury says.
But, many people aren't jumping up so fast. They say they're skeptical.
"It's like getting the flu virus. You didn't have it before and now you got it. And, I'm older so, I'm a diabetic so it probably wouldn't be good for me,"Ronnie Godwin of Cincoteague says.
Others worry about how the vaccine would affect them.
"I don't see it as a preventative and it's something that they're not even sure of what it will do. They don't know the side effects. Even with other flu shots per say, some people still get the flu with it,"Dellophine Henry of Salisbury says.
